ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $49.40 million. The enterprise value is $60.75 million.
Important Dates
The next confirmed earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 8.98 million shares outstanding. The number of shares has increased by 5.42% in one year.
| Current Share Class | 8.98M |
| Shares Outstanding | 8.98M |
| Shares Change (YoY) | +5.42% |
| Shares Change (QoQ) | +9.44% |
| Owned by Insiders (%) | 29.15% |
| Owned by Institutions (%) | 13.43% |
| Float | 5.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.70 |
| Forward PS | n/a |
| PB Ratio | 1.79 |
| P/TBV Ratio | 1.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 138.04 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.29 |
| EV / EBITDA | 41.78 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.55.
| Current Ratio | 3.41 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 7.75 |
| Debt / FCF | n/a |
| Interest Coverage | -2.17 |
Financial Efficiency
Return on equity (ROE) is -8.21% and return on invested capital (ROIC) is -1.83%.
| Return on Equity (ROE) | -8.21% |
| Return on Assets (ROA) | -1.73% |
| Return on Invested Capital (ROIC) | -1.83% |
| Return on Capital Employed (ROCE) | -3.03% |
| Revenue Per Employee | $353,242 |
| Profits Per Employee | -$28,755 |
| Employee Count | 75 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 2.43 |
Taxes
In the past 12 months, ImmuCell has paid $10,056 in taxes.
| Income Tax | 10,056 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.13% in the last 52 weeks. The beta is 0.39, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +9.13% |
| 50-Day Moving Average | 5.13 |
| 200-Day Moving Average | 4.41 |
| Relative Strength Index (RSI) | 58.31 |
| Average Volume (20 Days) | 38,289 |
Short Selling Information
The latest short interest is 4,465, so 0.05% of the outstanding shares have been sold short.
| Short Interest | 4,465 |
| Short Previous Month | 13,161 |
| Short % of Shares Out | 0.05% |
| Short % of Float | 0.08% |
| Short Ratio (days to cover) | 0.13 |
Income Statement
In the last 12 months, ImmuCell had revenue of $26.49 million and -$2.16 million in losses. Loss per share was -$0.26.
| Revenue | 26.49M |
| Gross Profit | 8.35M |
| Operating Income | -1.23M |
| Pretax Income | -3.89M |
| Net Income | -2.16M |
| EBITDA | 1.45M |
| EBIT | -1.23M |
| Loss Per Share | -$0.26 |
Full Income StatementBalance Sheet
The company has $3.76 million in cash and $15.10 million in debt, giving a net cash position of -$11.34 million or -$1.26 per share.
| Cash & Cash Equivalents | 3.76M |
| Total Debt | 15.10M |
| Net Cash | -11.34M |
| Net Cash Per Share | -$1.26 |
| Equity (Book Value) | 27.52M |
| Book Value Per Share | 3.06 |
| Working Capital | 10.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $357,903 and capital expenditures -$465,725, giving a free cash flow of -$107,822.
| Operating Cash Flow | 357,903 |
| Capital Expenditures | -465,725 |
| Free Cash Flow | -107,822 |
| FCF Per Share | -$0.01 |
Full Cash Flow StatementMargins
Gross margin is 31.51%, with operating and profit margins of -4.65% and -8.14%.
| Gross Margin | 31.51% |
| Operating Margin | -4.65% |
| Pretax Margin | -8.10% |
| Profit Margin | -8.14% |
| EBITDA Margin | 5.49% |
| EBIT Margin | -4.65% |
| FCF Margin | n/a |